APA (7th ed.) Citation

Ruperto N, Quartier P, Wulffraat N, Woo P, Loy A, Mouy R, . . . Rordorf C. (2008). 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA). BMC.

Chicago Style (17th ed.) Citation

Ruperto N, et al. 2.2 A Phase II Trial with Canakinumab, a New IL-1beta Blocking Monoclonal Antibody (ACZ885), to Evaluate Preliminary Dosing, Safety and Efficacy Profile in Children with Systemic Juvenile Idiopathic Arthritis (sJIA). BMC, 2008.

MLA (9th ed.) Citation

Ruperto N, et al. 2.2 A Phase II Trial with Canakinumab, a New IL-1beta Blocking Monoclonal Antibody (ACZ885), to Evaluate Preliminary Dosing, Safety and Efficacy Profile in Children with Systemic Juvenile Idiopathic Arthritis (sJIA). BMC, 2008.